TAI JACKSON P
TAI JACKSON P's purchase track record
TAI JACKSON P has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/12/2022 | LLY | $200K | +14.3% | +12.3% | -4.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Mastercard pushes stablecoin platform, seeks fee settlement approval. Recent reports show Mastercard’s stock joining record highs as investors rotate from chip stocks. The company is also asking a court to approve a fee settlement and has launched a new platform with BVNK that lets banks hold stablecoins and dollars together. Additionally, U.S. officials raised Mastercard’s market‑access issues with China in recent talks. Analysts continue to watch upcoming earnings for further guidance.
Transaction History
| LLY | ▲ Buy | Grant | 5 | $2K | 4/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 6 | $2K | 3/20/2023 | View on chart |
| LLY | ▲ Buy | Grant | 6 | $2K | 2/21/2023 | View on chart |
| LLY | ▲ Buy | Grant | 6 | $2K | 1/17/2023 | View on chart |
| LLY | ▲ Buy | Grant | 498 | $180K | 11/21/2022 | View on chart |
| LLY | ▲ Buy | Open Market | 656 | $200K | 8/12/2022 | View on chart |
| MA | ▲ Buy | Grant | 741 | $0 | 6/21/2022 | View on chart |
| LLY | ▲ Buy | Grant | 8 | $2K | 12/20/2021 | View on chart |
| LLY | ▲ Buy | Grant | 8 | $2K | 11/15/2021 | View on chart |
| LLY | ▲ Buy | Grant | 677 | $175K | 11/15/2021 | View on chart |
| LLY | ▲ Buy | Grant | 8 | $2K | 10/18/2021 | View on chart |
| LLY | ▲ Buy | Grant | 9 | $2K | 9/20/2021 | View on chart |
| LLY | ▲ Buy | Grant | 7 | $2K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.